Payment overview · 2025
General Payments
$212.88
2 reported records · 2 companies
Healthcare provider profile · identity verified
John E Stanhope, DO
Allopathic & Osteopathic Physicians|Family Medicine · NEW BRAUNFELS, TX · NPI 1740331016
Verified facts
What the public records show
CMS Open Payments records show John E Stanhope, DO received $212.88 in general payments during 2025 across 2 reported records.
AERIN MEDICAL INC. accounted for 63.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AERIN MEDICAL INC. | Unresolved — no canonical attribution shown | $135.00 | 63.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.88 | 36.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.88 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RHINAER STYLUS Normalized: rhinaer stylus |
Device | AERIN MEDICAL INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| VIVAER STYLUS Normalized: vivaer stylus |
Device | AERIN MEDICAL INC. | $135.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 260 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 242 | 66 |
| Lisinopril | Lisinopril | 235 | 71 |
| Gabapentin | Gabapentin | 228 | 59 |
| Metformin Hcl | Metformin Hcl | 154 | 56 |
| Losartan Potassium | Losartan Potassium | 137 | 45 |
| Metformin Hcl Er | Metformin Hcl | 121 | 36 |
| Trazodone Hcl | Trazodone Hcl | 120 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 38 |
| Alprazolam | Alprazolam | 99 | 17 |
| Omeprazole | Omeprazole | 97 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 28 |
| Clonazepam | Clonazepam | 70 | 11 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Simvastatin | Simvastatin | 69 | 18 |
| Carvedilol | Carvedilol | 67 | 18 |
| Tramadol Hcl | Tramadol Hcl | 67 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 14 |
| Farxiga | Dapagliflozin Propanediol | 61 | 18 |
| Glimepiride | Glimepiride | 61 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 14 |
| Ozempic | Semaglutide | 57 | 11 |
| Furosemide | Furosemide | 53 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 13 |
| Montelukast Sodium | Montelukast Sodium | 50 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 13 |
| Allopurinol | Allopurinol | 42 | 13 |
| Amoxicillin | Amoxicillin | 42 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 12 |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Eliquis | Apixaban | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | 11 |
| Glipizide | Glipizide | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 12 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 12 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 12 |
| Fluconazole | Fluconazole | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Prednisone | Prednisone | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $212.88 · 2 records | AERIN MEDICAL INC. | Ozempic, RHINAER STYLUS, VIVAER STYLUS | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error